Evidence map›Paper›PMID 36016503›Full record

SynthesisBMB reports2022

Methylation-sensitive high-resolution melting analysis of the USP44 promoter can detect early-stage hepatocellular carcinoma in blood samples.

Si-Cho Kim, Jiwon Kim, Da-Won Kim, Yanghee Choi, Kyunghyun Park, Eun Ju Cho, Su Jong Yu, Jeongsil Kim-Ha, Young-Joon Kim

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in BMB reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The Knockdown of USP34 Inhibits the Progression of Hepatocellular Carcinoma by Accelerating c-Myc Degradation.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Si-Cho KimInterdisciplinary Program of Integrated OMICS for Biomedical Science, Yonsei University, Seoul 03722, Korea.
Jiwon KimDepartment of Integrative Bioscience & Biotechnology, College of Life Sciences, Sejong University, Seoul 05006, Korea.
Da-Won KimInterdisciplinary Program of Integrated OMICS for Biomedical Science, Yonsei University, Seoul 03722, Korea.
Yanghee ChoiDepartment of Integrative Bioscience & Biotechnology, College of Life Sciences, Sejong University, Seoul 05006, Korea.
Kyunghyun ParkDepartment of Integrative Bioscience & Biotechnology, College of Life Sciences, Sejong University, Seoul 05006, Korea.
Eun Ju ChoDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea.
Su Jong YuDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea.
Jeongsil Kim-HaDepartment of Integrative Bioscience & Biotechnology, College of Life Sciences, Sejong University, Seoul 05006, Korea.
Young-Joon KimInterdisciplinary Program of Integrated OMICS for Biomedical Science, Yonsei University, Seoul 03722; Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea.
Sejong University · KRYonsei University · KRSeoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is dangerous cancer that often evades early detection because it is asymptomatic and an effective detection method is lacking. For people with chronic liver inflammation who are at high risk of developing HCC, a sensitive detection method for HCC is needed. In a meta-analysis of The Cancer Genome Atlas pan-cancer methylation database, we identified a CpG island in the USP44 promoter that is methylated specifically in HCC. We developed methylation-sensitive high-resolution melting (MS-HRM) analysis to measure the methylation levels of the USP promoter in cell-free DNA isolated from patients. Our MS-HRM assay correctly identified 40% of patients with early-stage HCC, whereas the α-fetoprotein test, which is currently used to detect HCC, correctly identified only 25% of early-stage HCC patients. These results demonstrate that USP44 MS-HRM analysis is suitable for HCC surveillance. [BMB Reports 2022; 55(11): 553-558].

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsBiomarkers, TumorCpG IslandsDNA MethylationHumansPromoter Regions, GeneticUbiquitin ThiolesteraseBiomarkers, TumorUbiquitin ThiolesteraseUSP44 protein, human

Identifiers

PMID36016503
PMCPMC9712700
OpenAlexW4298182027

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.